The efficacy of interleukin-1 (IL-1) inhibitors (anakinra, canakinumab) and interleukin-6 (IL-6) inhibitors (tocilizumab) as first-line biologic therapy for children with systemic juvenile idiopathic arthritis (sJIA) has been practically assured. The gene discussed is IL6; the disease is systemic-onset juvenile idiopathic arthritis.